Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722461 · ClinicalTrials.gov registry record · NA
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
A NA study, sponsored by Ulthera.
- Terminated
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT01722461: Clinical Trial NA study, sponsored by Ulthera.
NCT01722461 is a NA study that was terminated before completion, run by Ulthera. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01722461, a NA study, was terminated before completion, sponsored by Ulthera.
- TERMINATED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham treatments, also with the Ulthera System but with the energy settings on the device set to deliver no ultrasound energy. Subjects will be randomized in a 2:1 ratio, with 2 subjects randomized to active treatment for every one subject randomized to sham treatment. Subjects will receive 2 study treatments 30 days apart. Subjects and study personnel conducting efficacy measures will be blinded to the assigned treatment groups. The study hypothesis is that subjects in the active treatment group will have a greater reduction in underarm sweating compared to those in the sham group as measured by a quality of life questionnaire. All subjects will undergo follow-up assessments at 14 days and 30 days from the date of their first study treatment, and 14 days, 30 days, 3 months and 6 months from the date of their second study treatment. Subjects in the active treatment group will also undergo follow-up assessments at 9 months and 12 months from the date of their second study treatment.
Primary Outcome
As measured by the Hyperhidrosis Disease Severity Scale (HDSS), a quality of life questionnaire
Interventions
- DEVICE Ulthera System
- DEVICE Sham treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-11 |
| Phase | NA |
Why NCT01722461 stopped before completion
NCT01722461 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Ulthera System is the first listed.
NCT01722461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01722461 about?
NCT01722461 is a clinical study titled "A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis". This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham treatments, also with the Ulthera System but with the energy settings on ...
What is the current status of trial NCT01722461?
This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2012-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01722461?
The interventions under investigation include: Ulthera System (DEVICE), Sham treatment (DEVICE).
Who is sponsoring clinical trial NCT01722461?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01722461's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia